Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Consun Pharmaceutical Group Company

1681.HK
KYG2524A1031
A1XAEC

Price

7.10
Today +/-
+0.04
Today %
+4.05 %
P

Consun Pharmaceutical Group stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Consun Pharmaceutical Group stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Consun Pharmaceutical Group stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Consun Pharmaceutical Group stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Consun Pharmaceutical Group's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Consun Pharmaceutical Group Stock Price History

DateConsun Pharmaceutical Group Price
10/10/20247.10 undefined
10/9/20246.82 undefined
10/8/20246.90 undefined
10/7/20247.20 undefined
10/4/20246.95 undefined
10/3/20246.51 undefined
10/2/20246.72 undefined
9/30/20246.42 undefined
9/27/20246.10 undefined
9/26/20245.86 undefined
9/25/20245.87 undefined
9/24/20245.76 undefined
9/23/20245.60 undefined
9/20/20245.60 undefined
9/19/20245.46 undefined
9/17/20245.43 undefined
9/16/20245.42 undefined
9/13/20245.31 undefined

Consun Pharmaceutical Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Consun Pharmaceutical Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Consun Pharmaceutical Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Consun Pharmaceutical Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Consun Pharmaceutical Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Consun Pharmaceutical Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Consun Pharmaceutical Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Consun Pharmaceutical Group’s growth potential.

Consun Pharmaceutical Group Revenue, EBIT and net profit per share

DateConsun Pharmaceutical Group RevenueConsun Pharmaceutical Group EBITConsun Pharmaceutical Group Net Income
2026e3.86 B undefined1.39 B undefined1.21 B undefined
2025e3.38 B undefined1.2 B undefined1.05 B undefined
2024e2.98 B undefined1.01 B undefined901.94 M undefined
20232.59 B undefined825.92 M undefined784.53 M undefined
20222.34 B undefined715.41 M undefined682.91 M undefined
20212.04 B undefined660.18 M undefined590.17 M undefined
20201.75 B undefined550.13 M undefined498.79 M undefined
20191.73 B undefined496.38 M undefined79.82 M undefined
20181.84 B undefined655.33 M undefined465.35 M undefined
20171.66 B undefined533.43 M undefined396.24 M undefined
20161.22 B undefined399.39 M undefined307.53 M undefined
2015831.11 M undefined293.93 M undefined249.69 M undefined
2014730.68 M undefined235.46 M undefined211.2 M undefined
2013571.8 M undefined206.8 M undefined152.9 M undefined
2012457.8 M undefined179.2 M undefined136.2 M undefined
2011389.3 M undefined143.6 M undefined107.3 M undefined
2010303.7 M undefined102.3 M undefined79.3 M undefined

Consun Pharmaceutical Group Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
201020112012201320142015201620172018201920202021202220232024e2025e2026e
0.30.390.460.570.730.831.221.661.841.731.752.042.342.592.983.383.86
-28.3817.4824.9527.8513.8447.1735.7311.02-6.241.3916.6714.4310.7314.9413.6014.02
79.2175.3275.7179.1678.2280.6374.4973.9875.0972.9775.4074.7175.3374.17---
0.240.290.350.450.570.670.911.231.381.261.321.531.761.92000
0.10.140.180.210.240.290.40.530.660.50.550.660.720.831.011.21.39
33.6636.7639.1736.0832.1935.2632.6232.1135.5428.7031.3932.2930.5731.8533.9935.4836.02
0.080.110.140.150.210.250.310.40.470.080.50.590.680.780.91.051.21
-35.4427.1011.7638.8218.0123.2928.9917.42-83.01530.3818.4715.5914.9614.9215.9815.31
-----------------
-----------------
750750750758.9998.52981.57959.73867.11877.99854.47817.26804.7792799.17000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The Consun Pharmaceutical Group Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Consun Pharmaceutical Group is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (B)TOTAL CAPITAL (B)
20102011201220132014201520162017201820192020202120222023
                           
0.030.060.080.91.090.490.670.991.271.381.942.433.043.58
172.7215.7248.5225232.14363.7557.28970.29863.99763.81448.54351.23259.56255.84
25.77.857.511.5322.769.1515.7820.2828.449.8918.3436.154.13
34.920.422.44953.4871.01140.97200210.31210.68227.37243.04276.08367.09
6.37.287.49.24.812.739.99.0231.8323.4932.6216.911.5817.82
0.270.320.451.191.40.961.392.182.42.412.663.063.624.28
127.2150.9171.5232.3229.91223.77392.88400.8561.79661.31675.77724.63746.21739.06
2.62.62.62.62.6639.2621.1520.4817.216.6516.1215.6221.6323.86
0000000000018.3436.10
000000489.63460.22430.8396.07371.42341.66311.9283.14
000000320.65320.65320.6500000
30.727.626.929.433.994.67144.74185.23170.45224.41228.24224.99189.97183.85
0.160.180.20.260.270.961.371.391.51.31.291.331.311.23
0.430.50.651.461.661.922.763.573.93.713.954.384.935.51
                           
80.880.8078.378.2578.0776.2468.6568.7868.0364.4264.863.4563.81
000722.6684.6647.94454.13247.27187.91145.4019.79018.15
0.170.170.360.460.670.911.231.431.91.782.152.563.083.54
-0.2-0.2-0.2-0.20.170.210.360.340.352.821.691.852.081.84
00000000000000
0.250.250.361.261.431.641.761.752.161.992.222.653.153.63
0.030.020.030.020.040.040.080.070.090.060.050.070.061.03
41.539.746.659.673.2994.78237.38411.73446.17364.6406.42465.53566.13638.76
100.9165.7181.87068.5494.81229.62296.14313.03322.61325.14222.82270.24265.51
0000000000549.41599.3450.52503.42
013.600000193.62147.2553.5703.123.714.22
0.170.240.260.150.180.230.550.9711.31.331.361.352.44
0000000374.48245.34008.555.953.9
8.113.828.639.939.4940.2129.67142.41137.2288.2986.2669.378.0171.21
21.91.99.612.0211.5821.620.7418.3216.7415.6316.718.9319.18
10.115.730.549.551.5151.79151.27537.64400.87105.03101.8994.55102.8994.29
0.180.250.290.20.230.280.71.511.41.41.431.451.452.53
0.430.50.651.461.661.922.463.253.563.43.654.14.66.16
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Consun Pharmaceutical Group provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Consun Pharmaceutical Group's financial health and stability.

Assets

Consun Pharmaceutical Group's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Consun Pharmaceutical Group must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Consun Pharmaceutical Group after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Consun Pharmaceutical Group's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2010201120122013201420152016201720182019202020212022
103145179210264314403544616133583695746
11101112151940677173717275
0000000000000
-47-98-62-55-4-164-15-3683-280191-36165
200-419142186245619-6-40
0000001242224211210
82051434262629312016011518213
6856128163294184449252754383867725947
-17-31-37-64-20-17-25-54-193-179-53-98-51
-16-29-11116-248-45591-60-180-110-25-298-368
11-7480-227-438116-5126928-200-317
0000000000000
013-13000-90594-1971472559-177
0014852-45-53-81-2615-43-152-15-26
-7060640-104-81-358128-292-156-279-166-342
-70.00-7.00--30.00-21.00--72.00-31.00-32.00-34.00-21.00-12.00-10.00
000-181-38-28-114-173-68-225-131-198-127
-183216820-58-353182316280113557256253
51.22591.599.5273.75166.76424.15197.15560.86203.39813.36627.29896.09
0000000000000

Consun Pharmaceutical Group stock margins

The Consun Pharmaceutical Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Consun Pharmaceutical Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Consun Pharmaceutical Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Consun Pharmaceutical Group's sales revenue. A higher gross margin percentage indicates that the Consun Pharmaceutical Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Consun Pharmaceutical Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Consun Pharmaceutical Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Consun Pharmaceutical Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Consun Pharmaceutical Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Consun Pharmaceutical Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Consun Pharmaceutical Group Margin History

Consun Pharmaceutical Group Gross marginConsun Pharmaceutical Group Profit marginConsun Pharmaceutical Group EBIT marginConsun Pharmaceutical Group Profit margin
2026e74.19 %36.02 %31.26 %
2025e74.19 %35.48 %30.91 %
2024e74.19 %33.98 %30.29 %
202374.19 %31.89 %30.29 %
202275.35 %30.58 %29.19 %
202174.7 %32.29 %28.86 %
202075.4 %31.39 %28.46 %
201972.99 %28.72 %4.62 %
201875.08 %35.54 %25.24 %
201773.99 %32.13 %23.87 %
201674.46 %32.64 %25.14 %
201580.68 %35.37 %30.04 %
201478.25 %32.23 %28.9 %
201379.08 %36.17 %26.74 %
201275.73 %39.14 %29.75 %
201175.47 %36.89 %27.56 %
201079.03 %33.68 %26.11 %

Consun Pharmaceutical Group Stock Sales Revenue, EBIT, Earnings per Share

The Consun Pharmaceutical Group earnings per share therefore indicates how much revenue Consun Pharmaceutical Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Consun Pharmaceutical Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Consun Pharmaceutical Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Consun Pharmaceutical Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Consun Pharmaceutical Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Consun Pharmaceutical Group Revenue, EBIT and net profit per share

DateConsun Pharmaceutical Group Sales per ShareConsun Pharmaceutical Group EBIT per shareConsun Pharmaceutical Group Earnings per Share
2026e4.67 undefined0 undefined1.46 undefined
2025e4.09 undefined0 undefined1.26 undefined
2024e3.6 undefined0 undefined1.09 undefined
20233.24 undefined1.03 undefined0.98 undefined
20222.95 undefined0.9 undefined0.86 undefined
20212.54 undefined0.82 undefined0.73 undefined
20202.14 undefined0.67 undefined0.61 undefined
20192.02 undefined0.58 undefined0.09 undefined
20182.1 undefined0.75 undefined0.53 undefined
20171.91 undefined0.62 undefined0.46 undefined
20161.27 undefined0.42 undefined0.32 undefined
20150.85 undefined0.3 undefined0.25 undefined
20140.73 undefined0.24 undefined0.21 undefined
20130.75 undefined0.27 undefined0.2 undefined
20120.61 undefined0.24 undefined0.18 undefined
20110.52 undefined0.19 undefined0.14 undefined
20100.4 undefined0.14 undefined0.11 undefined

Consun Pharmaceutical Group business model

Consun Pharmaceutical Group Ltd is a leading Chinese pharmaceutical manufacturer. The company was founded in 1994 and is headquartered in Beijing, China. Consun Pharmaceutical specializes in the production, sale, and research of Chinese medicines. Please note that the translation provided is approximate and may not be an exact representation of the original text. Consun Pharmaceutical Group is one of the most popular companies on Eulerpool.com.

Consun Pharmaceutical Group SWOT Analysis

Strengths

Consun Pharmaceutical Group Ltd possesses several strengths that contribute to its competitive advantage in the market. Firstly, the company has a strong portfolio of high-quality and innovative pharmaceutical products. This enables Consun to meet the diverse healthcare needs of its customers effectively. Secondly, Consun has established a robust distribution network, allowing the company to reach a wide customer base. This network ensures efficient delivery of its products to various regions, enhancing customer satisfaction and market reach. Additionally, Consun enjoys a favorable reputation and brand recognition in the industry, earned through its commitment to quality, reliability, and customer-centric approach. This positive perception enables the company to attract and retain loyal customers, giving it an edge over competitors. Lastly, Consun benefits from a talented and experienced workforce. The company's skilled employees contribute to its effective research and development efforts, as well as the production and marketing of innovative pharmaceutical solutions.

Weaknesses

Despite its strengths, Consun Pharmaceutical Group Ltd faces certain weaknesses that pose challenges to its growth and market position. One notable weakness is the company's limited presence in international markets. This restricts its expansion opportunities and makes Consun vulnerable to changes in the domestic market. Furthermore, Consun may potentially face issues related to regulatory compliance. The pharmaceutical industry is subject to strict regulations and quality control standards, which can impact Consun's operations and product development processes. Ensuring full compliance can be resource-intensive and time-consuming. Another weakness lies in the company's heavy reliance on a few key products for a significant portion of its revenue. Any decline in the demand or popularity of these products could adversely affect Consun's financial performance and overall competitiveness. Lastly, Consun may possess limited brand recognition outside of its core customer base. This could hinder its ability to expand into new markets and compete effectively with established international players.

Opportunities

Consun Pharmaceutical Group Ltd has several opportunities to capitalize on and drive its future growth. Firstly, the emerging markets present significant growth prospects for the pharmaceutical industry. Consun can strategically expand its presence in these markets, tapping into the rising demand for healthcare products and services. Moreover, advancements in technology and digitalization offer opportunities for Consun to enhance its operations and customer engagement. By adopting digital platforms and investing in e-commerce capabilities, the company can improve its reach, accessibility, and customer convenience, gaining a competitive edge. Additionally, increasing awareness and demand for natural and herbal products provide Consun a chance to diversify its product offerings. By investing in research and development in this area, the company can cater to the evolving preferences of health-conscious consumers and expand its market share. Furthermore, partnerships and collaborations with other pharmaceutical companies, research institutions, or healthcare providers can enable Consun to access new resources, technologies, and markets. Such collaborations can foster innovation, accelerate product development, and generate new revenue streams.

Threats

Consun Pharmaceutical Group Ltd faces several threats that may impact its operations and market position. Firstly, intense competition within the pharmaceutical industry poses a threat to Consun's market share and profitability. Competitors may offer similar products, competitive pricing, or aggressive marketing strategies, challenging Consun's market dominance. Secondly, regulatory changes or stricter regulations in the healthcare industry can disrupt Consun's operations and increase compliance costs. These regulatory challenges may also delay product approvals and limit the company's ability to launch new products in a timely manner. Furthermore, patent expirations of key products pose a threat to Consun's revenue and market position. Once a product's patent expires, generic alternatives can enter the market and erode Consun's market share and pricing power. Lastly, unforeseen events like natural disasters or global economic downturns can disrupt Consun's supply chain, manufacturing operations, and demand for pharmaceutical products. Such disruptions can adversely affect the company's financial performance and stability.

Consun Pharmaceutical Group Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Consun Pharmaceutical Group historical P/E ratio, EBIT multiple, and P/S ratio

Consun Pharmaceutical Group shares outstanding

The number of shares was Consun Pharmaceutical Group in 2023 — This indicates how many shares 799.168 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Consun Pharmaceutical Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Consun Pharmaceutical Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Consun Pharmaceutical Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Consun Pharmaceutical Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Consun Pharmaceutical Group dividend history and estimates

In 2023, Consun Pharmaceutical Group paid a dividend amounting to 0.45 CNY. Dividend means that Consun Pharmaceutical Group distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Consun Pharmaceutical Group provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Consun Pharmaceutical Group’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Consun Pharmaceutical Group's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Consun Pharmaceutical Group Dividend History

DateConsun Pharmaceutical Group Dividend
2026e0.52 undefined
2025e0.52 undefined
2024e0.52 undefined
20230.45 undefined
20220.2 undefined
20210.3 undefined
20200.18 undefined
20190.3 undefined
20180.1 undefined
20170.25 undefined
20160.14 undefined
20150.04 undefined
20140.04 undefined

Consun Pharmaceutical Group dividend payout ratio

In 2023, Consun Pharmaceutical Group had a payout ratio of 31.2%. The payout ratio indicates the percentage of the company's profits that Consun Pharmaceutical Group distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Consun Pharmaceutical Group represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Consun Pharmaceutical Group could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Consun Pharmaceutical Group's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Consun Pharmaceutical Group Payout Ratio History

DateConsun Pharmaceutical Group Payout ratio
2026e30.56 %
2025e28.72 %
2024e31.77 %
202331.2 %
202223.19 %
202140.91 %
202029.49 %
2019321.16 %
201818.87 %
201753.83 %
201644.03 %
201513.95 %
201417.97 %
201331.2 %
201231.2 %
201131.2 %
201031.2 %
Unfortunately, there are currently no price targets and forecasts available for Consun Pharmaceutical Group.

Consun Pharmaceutical Group shareholders

%
Name
Stocks
Change
Date
25.13746 % An (Yubao)207,737,45503/23/2024
2.08796 % The Vanguard Group, Inc.17,254,994-158,0003/31/2024
16.47421 % Li (Quan)136,143,89903/23/2024
13.31670 % Young (Wai Po)110,050,000012/31/2022
1.75834 % An (Meng)14,531,000012/31/2022
1.09244 % Dimensional Fund Advisors, L.P.9,028,00001/31/2024
0.79471 % Fidelity Management & Research Company LLC6,567,534-9,9381/31/2024
0.51364 % Norges Bank Investment Management (NBIM)4,244,783-4,845,49912/31/2023
0.37355 % AllianceBernstein L.P.3,087,00002/29/2024
0.21890 % California State Teachers Retirement System1,809,000-809,0006/30/2023
1
2
3
4
...
5

Consun Pharmaceutical Group Executives and Management Board

Mr. Meng An51
Consun Pharmaceutical Group Executive Chairman of the Board and Chief Executive Officer (since 2021)
Compensation 13.84 M
Prof. Quan Zhu82
Consun Pharmaceutical Group Executive Director (since 2012)
Compensation 1.07 M
Mr. Hanxing Xu28
Consun Pharmaceutical Group Executive Director (since 2021)
Compensation 339,000
Ms. Yujun Chen42
Consun Pharmaceutical Group Independent Non-Executive Director
Compensation 156,000
Mr. Zhongshi Feng63
Consun Pharmaceutical Group Independent Non-Executive Director
Compensation 144,000
1
2
3

Consun Pharmaceutical Group Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Alibaba Group Holding Stock
Alibaba Group Holding
SupplierCustomer0,86-0,59-0,04-0,200,63-0,31
JD com A Stock
JD com A
SupplierCustomer0,810,12-0,03-0,29-0,15-
1

Most common questions regarding Consun Pharmaceutical Group

What values and corporate philosophy does Consun Pharmaceutical Group represent?

Consun Pharmaceutical Group Ltd represents values of innovation, integrity, and excellence, as well as a strong commitment to quality healthcare. The company's corporate philosophy focuses on meeting the healthcare needs of individuals and communities by providing safe and effective pharmaceutical products. Consun Pharmaceutical Group Ltd emphasizes research and development, constantly striving to introduce new and improved treatments to enhance people's wellbeing. By maintaining the highest standards of ethical conduct and social responsibility, Consun Pharmaceutical Group Ltd has become a trusted name in the industry. With its dedication to delivering top-quality healthcare solutions, the company aims to improve the quality of life for patients worldwide.

In which countries and regions is Consun Pharmaceutical Group primarily present?

Consun Pharmaceutical Group Ltd is primarily present in China, where it is based. As a leading pharmaceutical company, Consun focuses on research, development, manufacturing, and sales of innovative medicines and healthcare products. With a strong presence in the Chinese market, Consun has established a wide distribution network across various regions within China. The company's commitment to delivering high-quality healthcare solutions has contributed to its success and growth within the Chinese pharmaceutical industry.

What significant milestones has the company Consun Pharmaceutical Group achieved?

Consun Pharmaceutical Group Ltd has achieved several significant milestones. The company successfully obtained Good Manufacturing Practice (GMP) certification, indicating its adherence to quality standards. It has also expanded its product portfolio and established strong market presence in both domestic and international markets. Consun Pharmaceutical Group Ltd has consistently reported steady revenue growth and secured strategic partnerships with leading pharmaceutical companies. Additionally, the company has invested in research and development, leading to the launch of innovative and high-quality pharmaceutical products. Through its commitment to excellence and continuous growth, Consun Pharmaceutical Group Ltd has positioned itself as a reputable player in the pharmaceutical industry.

What is the history and background of the company Consun Pharmaceutical Group?

Consun Pharmaceutical Group Ltd is a renowned pharmaceutical company with a rich history and background. Founded in 1983, the company has grown to become a leading provider of high-quality and innovative healthcare solutions. Consun Pharmaceutical Group Ltd has established itself as a trusted name in the industry, focusing on research, development, production, and marketing of traditional Chinese medicines, chemical drugs, biologics, and other pharmaceutical products. With a commitment to excellence, the company has achieved significant milestones in the field of pharmaceuticals, catering to the healthcare needs of people worldwide. Consun Pharmaceutical Group Ltd's dedication to innovation and quality makes it a reliable player in the global pharmaceutical market.

Who are the main competitors of Consun Pharmaceutical Group in the market?

The main competitors of Consun Pharmaceutical Group Ltd in the market include Pfizer Inc., Johnson & Johnson, Novartis AG, and Roche Holding AG.

In which industries is Consun Pharmaceutical Group primarily active?

Consun Pharmaceutical Group Ltd is primarily active in the pharmaceutical industry. With a focus on research, development, manufacturing, and marketing of pharmaceutical products, Consun Pharmaceutical Group Ltd operates within the healthcare sector. This Chinese company specializes in producing and distributing both modern Western medicines and traditional Chinese medicines. Consun Pharmaceutical Group Ltd aims to provide high-quality and affordable healthcare solutions to the global market.

What is the business model of Consun Pharmaceutical Group?

Consun Pharmaceutical Group Ltd is a leading pharmaceutical company, specializing in the research, development, production, and sale of modern Chinese medicines. The core of their business model lies in integrating traditional Chinese medicine with advanced pharmaceutical technologies. Consun Pharmaceutical Group Ltd focuses on the production and distribution of prescription drugs, over-the-counter drugs, and healthcare products. By leveraging their strong research and development capabilities, they strive to deliver high-quality pharmaceutical products that cater to the healthcare needs of individuals. With a customer-centric approach, Consun Pharmaceutical Group Ltd continues to enhance their product offerings while maintaining their commitment to improving the overall well-being of the community.

What is the P/E ratio of Consun Pharmaceutical Group 2024?

The Consun Pharmaceutical Group P/E ratio is 6.29.

What is the P/S ratio of Consun Pharmaceutical Group 2024?

The Consun Pharmaceutical Group P/S ratio is 1.91.

What is the Quality Investing of Consun Pharmaceutical Group?

The Quality Investing for Consun Pharmaceutical Group is 10/10.

What is the revenue of Consun Pharmaceutical Group 2024?

The expected Consun Pharmaceutical Group revenue is 2.98 B CNY.

How high is the profit of Consun Pharmaceutical Group 2024?

The expected Consun Pharmaceutical Group profit is 901.94 M CNY.

What is the business model of Consun Pharmaceutical Group

The Consun Pharmaceutical Group Ltd is a Chinese company specializing in the manufacturing and sale of pharmaceutical products, as well as the development of medical technologies. The company operates in three main divisions: Pharmaceuticals, Medical Devices, and Health Services. The Pharmaceuticals division includes the production and sale of pharmaceutical products, including prescription drugs, over-the-counter medications, and health products. The company produces a wide range of medicines, including drugs for the treatment of cardiovascular diseases, diabetes, cancer, infectious diseases, and other conditions. Additionally, Consun also offers alternative medicine products based on oriental healing methods and natural ingredients. The second division, Medical Devices, produces and sells medical equipment and devices such as ultrasound machines, X-ray machines, CT scanners, and other medical instruments. The company has a strong presence in the Chinese market and is striving for further international expansion. Finally, Consun offers health services, including health and wellness programs, medical examinations and diagnostics, hospital administration, and pharmaceutical research and development. There is a network of health centers and clinics throughout China that provide consultations, examinations, and treatments. In terms of research and development, Consun is constantly working to develop innovative technologies and therapies, particularly in the field of cancer drugs and personalized medicine. The company has a strong and growing presence in the international research and development sector and actively collaborates with various institutions and universities. In summary, Consun Pharmaceutical Group Ltd offers a wide range of products and services in the healthcare field, including pharmaceutical products, medical devices, and health services. The company has a strong presence in the Chinese market and is striving for further international expansion. Finally, Consun aims to be innovative and develop new technologies and therapies.

What is the Consun Pharmaceutical Group dividend?

Consun Pharmaceutical Group pays a dividend of 0.2 CNY distributed over payouts per year.

How often does Consun Pharmaceutical Group pay dividends?

The dividend cannot currently be calculated for Consun Pharmaceutical Group or the company does not pay out a dividend.

What is the Consun Pharmaceutical Group ISIN?

The ISIN of Consun Pharmaceutical Group is KYG2524A1031.

What is the Consun Pharmaceutical Group WKN?

The WKN of Consun Pharmaceutical Group is A1XAEC.

What is the Consun Pharmaceutical Group ticker?

The ticker of Consun Pharmaceutical Group is 1681.HK.

How much dividend does Consun Pharmaceutical Group pay?

Over the past 12 months, Consun Pharmaceutical Group paid a dividend of 0.45 CNY . This corresponds to a dividend yield of about 6.33 %. For the coming 12 months, Consun Pharmaceutical Group is expected to pay a dividend of 0.52 CNY.

What is the dividend yield of Consun Pharmaceutical Group?

The current dividend yield of Consun Pharmaceutical Group is 6.33 %.

When does Consun Pharmaceutical Group pay dividends?

Consun Pharmaceutical Group pays a quarterly dividend. This is distributed in the months of July, October, July, October.

How secure is the dividend of Consun Pharmaceutical Group?

Consun Pharmaceutical Group paid dividends every year for the past 13 years.

What is the dividend of Consun Pharmaceutical Group?

For the upcoming 12 months, dividends amounting to 0.52 CNY are expected. This corresponds to a dividend yield of 7.32 %.

In which sector is Consun Pharmaceutical Group located?

Consun Pharmaceutical Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Consun Pharmaceutical Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Consun Pharmaceutical Group from 9/20/2024 amounting to 0.3 CNY, you needed to have the stock in your portfolio before the ex-date on 9/5/2024.

When did Consun Pharmaceutical Group pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of Consun Pharmaceutical Group in the year 2023?

In the year 2023, Consun Pharmaceutical Group distributed 0.2 CNY as dividends.

In which currency does Consun Pharmaceutical Group pay out the dividend?

The dividends of Consun Pharmaceutical Group are distributed in CNY.

All fundamentals about Consun Pharmaceutical Group

Our stock analysis for Consun Pharmaceutical Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Consun Pharmaceutical Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.